The MTHFR 677C→T polymorphism and risk of prostate cancer: Results from the CAPS study

Cancer Causes and Control

Volumn 18, Issue 10, 2007, Pages 1169-1174

  Johansson, Mattias ^a   Van Guelpen, Bethany ^a   Hultdin, Johan ^a   Wiklund, Fredrik ^b   Adami, Hans Olov ^b,c   Bälter, Katarina ^b   Grönberg, Henrik ^b   Stattin, Pär ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c HARVARD UNIVERSITY   (United States)

Author keywords

Genotype; MTHFR 677; Prostate cancer; SNP

Indexed keywords

AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; AGE; ALLELE; CASE CONTROL STUDY; DNA METHYLATION; DNA REPAIR; ENZYMOLOGY; GENETICS; HOMOZYGOTE; METABOLISM; MIDDLE AGED; PROSTATE TUMOR; RISK FACTOR; SWEDEN;

METHYLENETETRAHYDROFOLATE DEHYDROGENASE (NAD);

AGE FACTORS; ALLELES; CASE-CONTROL STUDIES; DNA METHYLATION; DNA REPAIR; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE (NAD+); MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS; SWEDEN;

EID: 34848913488     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-007-9055-z     Document Type: Article

References (24)

1. Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Curtis Ellison R et al (2001) The 1298A->C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 156(2):409-415
2. Davey Smith G, Ebrahim S (2003) 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32(1):1-22
3. Rakyan VK, Hildmann T, Novik KL, Lewin J, Tost J, Cox AV et al (2004) DNA methylation profiling of the human major histocompatibility complex: a pilot study for the human epigenome project. PLoS Biol 2(12):e405
4. Lin J, Spitz MR, Wang Y, Schabath MB, Gorlov IP, Hernandez LM et al (2004) Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study. Carcinogenesis 25(9):1639-1647
5. Nelson WG, De Marzo AM, Isaacs WB (2003) Prostate cancer. N Engl J Med 349(4):366-381
6. Fenech M (2001) The role of folic acid and Vitamin B12 in genomic stability of human cells. Mutat Res 475(1-2):57-67
7. Van Guelpen BR, Wiren SM, Bergh AR, Hallmans G, Stattin PE, Hultdin J (2006) Polymorphisms of methylenetetrahydrofolate reductase and the risk of prostate cancer: a nested case-control study. Eur J Cancer Prev 15(1):46-50
8. Singal R, Ferdinand L, Das PM, Reis IM, Schlesselman JJ (2004) Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk. Int J Oncol 25(5):1465-1471
9. Heijmans BT, Boer JM, Suchiman HE, Cornelisse CJ, Westendorp RG, Kromhout D et al (2003) A common variant of the methylenetetrahydrofolate reductase gene (1p36) is associated with an increased risk of cancer. Cancer Res 63(6):1249-1253
10. Cicek MS, Nock NL, Li L, Conti DV, Casey G, Witte JS (2004) Relationship between methylenetetrahydrofolate reductase C677T and A1298C genotypes and haplotypes and prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 13(8):1331-1336
11. Kimura F, Franke KH, Steinhoff C, Golka K, Roemer HC, Anastasiadis AG et al (2000) Methyl group metabolism gene polymorphisms and susceptibility to prostatic carcinoma. Prostate 45(3):225-231
12. Lindmark F, Zheng SL, Wiklund F, Bensen J, Balter KA, Chang B et al (2004) H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 96(16):1248-1254
13. National Prostate Cancer Register (2002)
14. Sobin LH, Wittekind C (2002) TNM Classification of Malignant Tumours, 6th ed. Wiley-Liss, New York
15. Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Rinaldi S et al (2006) Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 94(2):299-307
16. Breslow NE, Day NE (1980) Statistical methods in cancer research: Iarc scientific publications
17. Allison P (1999) Logistic regression using SAS: theory and application. SAS institute Press, Cary, North Carolina, 302 p
18. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10(1):111-113
19. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE (2001) Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 22(4):195-201
20. Wilcken B, Bamforth F, Li Z, Zhu H, Ritvanen A, Renlund M et al (2003) Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J Med Genet 40(8):619-625
21. George L, Mills JL, Johansson AL, Nordmark A, Olander B, Granath F et al (2002) Plasma folate levels and risk of spontaneous abortion. Jama 288(15):1867-1873
22. Lucock M, Yates Z (2005) Folic acid - vitamin and panacea or genetic time bomb? Nat Rev Genet 6(3):235-240
23. Schaedel C, Hjelte L, de Monestrol I, Johannesson M, Kollberg H, Kornfalt R et al (1999) Three common CFTR mutations should be included in a neonatal screening programme for cystic fibrosis in Sweden. Clin Genet 56(4):318-322
24. Stattin P, Johansson R, Damber JE, Hellstrom M, Hugosson J, Lundgren R et al (2003) Non-systematic screening for prostate cancer in Sweden-survey from the National Prostate Cancer Registry. Scand J Urol Nephrol 37(6):461-465